UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 353

Sortiert nach

Anticancer Cytokines: Biology and Clinical Effects of Interferon-α2, Interleukin (IL)-2, IL-15, IL-21, and IL-12

Seminars in oncology, 2015-08, Vol.42 (4), p.539-548

2015

Link zum Volltext

Verfügbarkeit prüfen

The use of immunotherapy in the treatment of melanoma

Journal of hematology and oncology, 2017-04, Vol.10 (1), p.88-88, Article 88

2017

Link zum Volltext

Verfügbarkeit prüfen

Immunotherapy of cancer in 2012

CA: a cancer journal for clinicians, 2012-09, Vol.62 (5), p.309-335

2012

Link zum Volltext

Verfügbarkeit prüfen

Avoiding Severe Toxicity From Combined BRAF Inhibitor and Radiation Treatment: Consensus Guidelines from the Eastern Cooperative Oncology Group (ECOG)

International journal of radiation oncology, biology, physics, 2016-06, Vol.95 (2), p.632-646

2016

Link zum Volltext

Verfügbarkeit prüfen

Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab

PloS one, 2014-02, Vol.9 (2), p.e87705-e87705

2014

Link zum Volltext

Verfügbarkeit prüfen

Systematic evaluation of the predictive gene expression signatures of immune checkpoint inhibitors in metastatic melanoma

Molecular carcinogenesis, 2023-01, Vol.62 (1), p.77-89

2023

Link zum Volltext

Verfügbarkeit prüfen

Systemic adjuvant therapy for high-risk cutaneous melanoma

Therapeutic Advances in Medical Oncology, 2022-10, Vol.14, p.175883592211340-17588359221134087

2022

Link zum Volltext

Verfügbarkeit prüfen

Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma

Journal for immunotherapy of cancer, 2015-09, Vol.3 (1), p.39-39, Article 39

2015

Link zum Volltext

Verfügbarkeit prüfen

Adjuvant Therapy for High-Risk Melanoma: An In-Depth Examination of the State of the Field

Cancers, 2023-08, Vol.15 (16), p.4125

2023

Link zum Volltext

Verfügbarkeit prüfen

Single-cell Characterization of the Cellular Landscape of Acral Melanoma Identifies Novel Targets for Immunotherapy

Clinical cancer research, 2022-05, Vol.28 (10), p.2131-2146

2022

Link zum Volltext

Verfügbarkeit prüfen

A Tumor and Immune-Related Micro-RNA Signature Predicts Relapse-Free Survival of Melanoma Patients Treated with Ipilimumab

International journal of molecular sciences, 2023-05, Vol.24 (9), p.8167

2023

Link zum Volltext

Verfügbarkeit prüfen

Long term impact of CTLA4 blockade immunotherapy on regulatory and effector immune responses in patients with melanoma

Journal of translational medicine, 2018-07, Vol.16 (1), p.184-184, Article 184

2018

Link zum Volltext

Verfügbarkeit prüfen

Safety and Efficacy of Combination Immunotherapy With Interferon Alfa-2b and Tremelimumab in Patients With Stage IV Melanoma

Journal of clinical oncology, 2012-01, Vol.30 (3), p.322-328

2012

Link zum Volltext

Verfügbarkeit prüfen

Leptomeningeal Disease (LMD) in Patients with Melanoma Metastases

Cancers, 2023-03, Vol.15 (6), p.1884

2023

Link zum Volltext

Verfügbarkeit prüfen

CTLA-4 blockade and interferon-α induce proinflammatory transcriptional changes in the tumor immune landscape that correlate with pathologic response in melanoma

PloS one, 2021-01, Vol.16 (1), p.e0245287-e0245287

2021

Link zum Volltext

Verfügbarkeit prüfen

Next Generation of Immunotherapy for Melanoma

Journal of clinical oncology, 2008-07, Vol.26 (20), p.3445-3455

2008

Link zum Volltext

Verfügbarkeit prüfen

The current state of adjuvant therapy of melanoma

The lancet oncology, 2020-11, Vol.21 (11), p.1394-1395

Tarhini, Ahmad A

2020

Link zum Volltext

Verfügbarkeit prüfen

The impact of CTLA-4 blockade and interferon-α on clonality of T-cell repertoire in the tumor microenvironment and peripheral blood of metastatic melanoma patients

Oncoimmunology, 2019-11, Vol.8 (11), p.e1652538-e1652538

2019

Link zum Volltext

Verfügbarkeit prüfen

Immunotherapy of Melanoma

Current molecular pharmacology, 2016-08, Vol.9 (3), p.196

Tarhini, Ahmad A

2016

Link zum Volltext

Verfügbarkeit prüfen

Annual Hospital Volume of High Dose Interleukin-2 and Inpatient Mortality in Melanoma and Renal Cell Carcinoma Patients

PloS one, 2016-01, Vol.11 (1), p.e0147153

2016

Link zum Volltext

Verfügbarkeit prüfen

Prognostic Significance of Serum S100B Protein in High-Risk Surgically Resected Melanoma Patients Participating in Intergroup Trial ECOG 1694

Journal of clinical oncology, 2009-01, Vol.27 (1), p.38-44

2009

Link zum Volltext

Verfügbarkeit prüfen

CTLA-4 blockade: therapeutic potential in cancer treatments

OncoTargets and therapy, 2010-06, Vol.3 (default), p.15-25

2010

Link zum Volltext

Verfügbarkeit prüfen

Enhanced immune activation within the tumor microenvironment and circulation of female high-risk melanoma patients and improved survival with adjuvant CTLA4 blockade compared to males

Journal of translational medicine, 2022-06, Vol.20 (1), p.253-253, Article 253

2022

Link zum Volltext

Verfügbarkeit prüfen

Sensitivity of treatment-free survival to subgroup analyses in patients with advanced melanoma treated with immune checkpoint inhibitors

Melanoma research, 2022-02, Vol.32 (1), p.35

2022

Link zum Volltext

Verfügbarkeit prüfen

How much of a good thing? What duration for interferon alfa-2b adjuvant therapy?

Journal of clinical oncology, 2012-11, Vol.30 (31), p.3773-3776

2012

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 353

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(328)
Mit Volltextzugriff
(323)

Publikationsform

Artikel
(343)
Buchkapitel
(6)
Berichte
(2)
Texte
(2)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Journal Of Clinical Oncology
(93)
Journal For Immunotherapy Of Cancer
(31)
Cancer Research
(22)
Cancer
(12)
Clinical Cancer Research
(9)
Journal Of Translational Medicine
(9)
Plos One
(9)
Melanoma Research
(8)
Cancers
(6)
Nature Clinical Practice. Oncology
(5)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Anticancer Cytokines: Biology and Clinical Effects of Interferon-α2, Interleukin (IL)-2, IL-15, IL-21, and IL-12

The use of immunotherapy in the treatment of melanoma

Immunotherapy of cancer in 2012

Avoiding Severe Toxicity From Combined BRAF Inhibitor and Radiation Treatment: Consensus Guidelines from the Eastern Cooperative Oncology Group (ECOG)

Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab

Systematic evaluation of the predictive gene expression signatures of immune checkpoint inhibitors in metastatic melanoma

Systemic adjuvant therapy for high-risk cutaneous melanoma

Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma

Adjuvant Therapy for High-Risk Melanoma: An In-Depth Examination of the State of the Field

Single-cell Characterization of the Cellular Landscape of Acral Melanoma Identifies Novel Targets for Immunotherapy

A Tumor and Immune-Related Micro-RNA Signature Predicts Relapse-Free Survival of Melanoma Patients Treated with Ipilimumab

Long term impact of CTLA4 blockade immunotherapy on regulatory and effector immune responses in patients with melanoma

Safety and Efficacy of Combination Immunotherapy With Interferon Alfa-2b and Tremelimumab in Patients With Stage IV Melanoma

Leptomeningeal Disease (LMD) in Patients with Melanoma Metastases

CTLA-4 blockade and interferon-α induce proinflammatory transcriptional changes in the tumor immune landscape that correlate with pathologic response in melanoma

Next Generation of Immunotherapy for Melanoma

The current state of adjuvant therapy of melanoma

The impact of CTLA-4 blockade and interferon-α on clonality of T-cell repertoire in the tumor microenvironment and peripheral blood of metastatic melanoma patients

Immunotherapy of Melanoma

Annual Hospital Volume of High Dose Interleukin-2 and Inpatient Mortality in Melanoma and Renal Cell Carcinoma Patients

Prognostic Significance of Serum S100B Protein in High-Risk Surgically Resected Melanoma Patients Participating in Intergroup Trial ECOG 1694

CTLA-4 blockade: therapeutic potential in cancer treatments

Enhanced immune activation within the tumor microenvironment and circulation of female high-risk melanoma patients and improved survival with adjuvant CTLA4 blockade compared to males

Sensitivity of treatment-free survival to subgroup analyses in patients with advanced melanoma treated with immune checkpoint inhibitors

How much of a good thing? What duration for interferon alfa-2b adjuvant therapy?

Suchergebnisse filtern